ClinicalTrials.gg
TerminatedNCT02292823e-MASTERUpdated Sep 2, 2015

MGuard™ Prime Embolic Protection Stent in Patients With Acute ST Elevation Myocardial Infarction

An observational study in ST Elevation Myocardial Infarction, sponsored by InspireMD. Terminated at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-02.

Sponsored by InspireMD · Observational

How we know

Why this study was terminated
Enrolment rate

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
63
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 43 studies in ST Elevation Myocardial Infarction with a site in Netherlands — 4 open to participants now, 8 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · Netherlands.

Started
2014
with 3 others
Observational
9 of 43
1 open now
Registered
18th of 43
by date
Lead sponsor
2 of 43
InspireMD

Among the 43 studies in ST Elevation Myocardial Infarction with a site in Netherlands, this one is one of 4 that started in 2014, is one of 9 observational ones, and was the 18th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

4 of the 43 studies in ST Elevation Myocardial Infarction with a site in Netherlands are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in ST Elevation Myocardial Infarction with a site in Netherlands, or all of them as a file.
02

Study summary

Prospective, non-randomized, single arm, multicenter observational study. The objective is to evaluate the safety and efficacy of the MGuard™ Prime stent in the treatment of de novo stenotic lesions in coronary arteries in patients undergoing primary percutaneous coronary intervention (PCI) due to acute ST elevation myocardial infarction (STEMI) in a real-world setting.

03

Conditions studied

  • ST Elevation Myocardial Infarction

Keywords

  • STEMI
  • heart attack
  • stent
  • Bare Metal Stent
  • myocardial infarction
  • PCI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects undergoing primary revascularization for STEMI and who are intended to undergo primary PCI with the MGuard™ Prime Embolic Protection Stent System.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is >18 years of age.
  2. Subject is experiencing clinical symptoms consistent with ST elevation acute myocardial infarction (STEMI) of >30 minutes and \<24 hours.
  3. Based on coronary anatomy, primary PCI is indicated for the culprit lesion with anticipated use of stenting.
  4. Subject agrees to all required follow-up procedures and visits and has provided where required.
  5. The target lesion is a de novo lesion in a native coronary artery.
  6. The reference vessel diameter (RVD) of the infarct lesion is 2.75-4.0 mm by visual assessment.

Exclusion criteria

Exclusion Criteria:

  1. Subject undergoing cardiopulmonary resuscitation.
  2. Cardiogenic shock (SBP \<80 mmHg for >30 minutes, or requiring IV pressors or intra-aortic balloon bump (IABP) or other hemodynamic support device for hypotension).
  3. Co-morbid condition(s) or others that could limit the subject's ability to participate in the trial or to comply with follow-up requirements, or impact the scientific integrity of the trial.
  4. Target lesion involves a bifurcation with a side branch >/=2.0 mm in diameter.
  5. In the Investigator's opinion the lesion/vessel is unsuitable for treatment with the MGuard™ Prime Embolic Protection Stent System for any reason.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
63 participants (actual)
Target follow-up
12 Months
Patient registry
Yes

Interventions

  • DeviceMGuard™ Prime Embolic Protection Stent System

    Also known as: MGuard™ Prime EPS

06

What researchers measure

Primary outcomes

  1. Complete ST-segment resolution

    Time frame: 1 day

  2. All cause death or MI at 30 days

    Time frame: 30 days

Secondary outcomes

  1. TIMI flow grade

    Time frame: 1 day

  2. Major Adverse Cardiac Events rate (MACE): cardiac death, re-MI, clinically-driven target lesion revascularization (TLR)

    Time frame: Discharge, 30 days, 6 months, 12 months

  3. Acute success rates

    Time frame: 1 day

  4. Stent thrombosis rate

    Time frame: Discharge, 30 days, 6 months,12 months

07

Study locations

1 site
  • Onze Lieve Vrouwe Gasthuis
    Amsterdam, Netherlands
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Sep 2015 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2014
First posted
Nov 17, 2014
Start
Apr 2014
Primary completionEst.
Sep 2015
CompletionEst.
Sep 2016
Last update
Sep 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02292823
Lead sponsor
InspireMD
Responsible party
Sponsor
First posted
Nov 17, 2014
Start date
Apr 2014
Primary completion
Sep 2015 (estimated)
Completion
Sep 2016 (estimated)
Last update
Sep 2, 2015

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion